Nivolumab 40mg/4mL (10mg/mL) Injection$18.00
1–9 boxes
$18.00 each
10–24 boxes
8% off
25+ boxes
10% off
Nivolumab 40mg/4mL (10mg/mL) Injection
SKU GME1327Oncology Care
Product Introduction
Nivolumab 40mg/4mL (10mg/mL) is an immune-checkpoint inhibitor for selected advanced or high-risk cancers. Its use depends on tumour type, stage, biomarkers and the planned single-agent or combination regimen.
How to use
A clinical team dilutes and administers the medicine as an intravenous infusion. Treatment interval and dose follow the cancer-specific protocol. It is not an intravenous push or a self-injection.
How it works
Nivolumab blocks PD-1 on T cells, reducing an inhibitory immune signal and allowing immune cells to attack susceptible cancer cells.
Side effects
Fatigue, rash, itching, diarrhoea and musculoskeletal pain can occur. Immune inflammation can affect the lungs, bowel, liver, kidneys, heart or hormone-producing glands.
Important information
Report new symptoms during treatment and for months afterwards. Previous autoimmune disease, organ transplantation or immune-suppressing treatment matters. Liver, kidney and thyroid tests help detect immune-related effects.
Uses
- Selected melanoma, lung, renal-cell, head-and-neck, liver and other cancers in established disease-specific settings.
Benefits
Reactivating antitumour immunity can provide durable disease control in some responsive patients.
Is immunotherapy the same as chemotherapy?
No. It changes immune signalling rather than directly damaging rapidly dividing cells in the same way as conventional chemotherapy.
Can side effects begin after treatment ends?
Yes. Immune-related inflammation may occur weeks or months after the last infusion.
Why report even a new mild diarrhoea pattern?
A change can be an early sign of immune-mediated colitis, which is easier to manage before it becomes severe.
Why should I report new excessive thirst or frequent urination during nivolumab treatment?
These can be signs of immune-related diabetes. Blood glucose needs prompt assessment, especially if thirst comes with vomiting, abdominal pain, unusual drowsiness or rapid breathing.
PD-1: an inhibitory receptor on immune T cells. Checkpoint inhibitor: a medicine that releases an immune brake. Immune-mediated: caused by immune-system activity.; AR: Nivolumab 40mg/4mL (10mg/mL) حقن; FR: Nivolumab 40mg/4mL (10mg/mL) injection; PT: Nivolumab 40mg/4mL (10mg/mL) injeção; ES: Nivolumab 40mg/4mL (10mg/mL) inyección; RU: Nivolumab 40mg/4mL (10mg/mL) инъекция; ID: Nivolumab 40mg/4mL (10mg/mL) suntikan; VI: Nivolumab 40mg/4mL (10mg/mL) thuốc tiêm; MS: Nivolumab 40mg/4mL (10mg/mL) suntikan; TL: Nivolumab 40mg/4mL (10mg/mL) iniksyon; ZH-SG: Nivolumab 40mg/4mL (10mg/mL) 注射剂